Workflow
Rare Neuromuscular Diseases
icon
Search documents
Dyne Therapeutics (NasdaqGS:DYN) FY Earnings Call Presentation
2026-01-15 01:15
Advancing Clinically Validated Platform Toward Commercialization This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this presentation, including statements regarding Dyne's strategy, future operations, prospects and plans, objectives of management, the potential of the FORCE platform and its conjugates, the therapeutic potential of zeleciment basivarsen (z-basivarsen, also known as DYN ...